Aurora Rejects Curaleaf's $5 Bid, Opens Its Books to Rivals

Aurora Cannabis's board has answered Curaleaf's raised offer. On October 14, it told shareholders to reject the revised bid, worth an implied US$5.00 a share, and to take no action before the offer expires on December 4. The board's formal response, a Notice of Change to its directors' circular filed the next day, goes further. It says Aurora's financial advisor has been soliciting other buyers since September, and Aurora has signed confidentiality and standstill agreements with "multiple parties" who are now reviewing its confidential information.

Curaleaf has not been given that access. "The Board has locked out Curaleaf while granting diligence access to unnamed parties," Chairman and CEO Boris Jordan said in Curaleaf's October 19 response. The Curaleaf-Aurora takeover fight now has one public bidder and an unknown number of possible rivals doing their diligence in private.

Why Aurora rejected Curaleaf's $5 bid

The notice gives six reasons. Three come with numbers:

• The cash. The US$1.00 cash portion of the offer totals about US$67 million. Aurora says it held US$108 million in cash and related items at June 30. In its words, Curaleaf "continues to propose to use Aurora Shareholders' own cash" to buy control.
• The stock. About 80% of the consideration is Curaleaf shares. Of the roughly US$1.00 increase in the headline price, Aurora says US$0.25 is new cash and about US$0.75 comes from the higher exchange ratio. The value of the raise depends on Curaleaf's share price.
• Curaleaf's balance sheet. Aurora puts Curaleaf's debt, leases, and financing obligations at about US$1.1 billion. That includes US$500 million of 11.5% senior secured notes. Aurora also points to a US$468 million uncertain tax liability on Curaleaf's books.

The other three: the bid is "opportunistic," Curaleaf hasn't backed up its estimate of at least US$40 million in annual cost savings, and better offers "may emerge" from the strategic review. Aurora's advisor, Fort Capital, delivered an updated opinion that the revised offer "remains inadequate from a financial point of view."

The sale process Curaleaf can't see

The notice includes a timeline:

• September 8: Aurora's special committee approved Fort Capital's plan to solicit other proposals.
• September 22: Parties that had signed nondisclosure agreements were given access to confidential information.
• October 6: Management and Fort Capital briefed the committee on due diligence and on when to expect expressions of interest.

Aurora hasn't named the parties or said how many there are. The only name reported so far is Organigram. The trade outlet Cultivated reported that Aurora has held talks with Organigram, and neither company has confirmed them. We covered that report and Curaleaf's raised bid on October 12. British American Tobacco owns nearly 30% of Organigram, according to Moby. Aurora's release says "there can be no assurance that the process will result in a transaction."

Curaleaf has also flagged a detail in Aurora's own filing: Fort Capital's advisory fees "may be contingent on the Company arriving at an alternative transaction." Fort Capital's fee for the fairness opinion itself is payable whatever the opinion concludes.

One regulatory dispute has ended. Aurora's notice says its application to the Alberta Securities Commission to make Curaleaf amend its bid "was no longer necessary and would be withdrawn" after Curaleaf's October 6 filing. Neither company has disclosed a ruling on Curaleaf's separate application over Aurora's at-the-market share sales.

What happens next

The offer runs until December 4, and it still needs more than 50% of the shares held by independent holders, a condition Curaleaf can't waive. Aurora's board says it will make a further recommendation once the review is finished. Curaleaf reports third-quarter results on November 3, the first chance for analysts to ask how far it will go.

What this means if you sell to Curaleaf stores

Watch the cash portion. Aurora's filing focuses on how little of the offer is cash and how much debt Curaleaf already carries. Analyst Pablo Zuanic has estimated that Curaleaf could raise the cash portion from US$1.00 to US$2.50 before its debt becomes a problem, Moby reported. Our read is that any increase in cash for Aurora is money Curaleaf isn't spending on its U.S. stores, so vendors should expect continued scrutiny of costs and payment terms.

A loss could free up attention. If a rival wins Aurora, Curaleaf keeps its cash and its management can go back to the U.S. business. The offer doesn't expire for more than five weeks.

This is reporting on public filings, not investment or legal advice.

FAQ

Did Aurora reject Curaleaf's offer? Yes. On October 14, 2026, Aurora's board, on its special committee's unanimous recommendation, told shareholders to reject Curaleaf's revised bid and take no action.

Who else is bidding for Aurora? No other offer has been announced. Aurora has signed confidentiality and standstill agreements with multiple unnamed parties. Organigram has been reported to have held talks with Aurora, but neither company has confirmed it.

When does Curaleaf's offer for Aurora expire? December 4, 2026, at 11:59 p.m. Mountain Time, unless it is extended or withdrawn.

What is Curaleaf offering for Aurora? US$1.00 in cash plus 0.4013 Curaleaf shares per Aurora share, an implied US$5.00 when announced, capped at US$6.00.

---

Curaleaf will spend at least the next five weeks on Aurora. If you sell in Curaleaf's markets, the independent dispensaries there are worth a call this quarter. See verified, owner-level contacts for independent dispensaries, refreshed weekly. Free preview at holdenleads.com.